Why Edesa Biotech, Inc.’s (EDSA) Stock Is Up 5.72%
As of Wednesday, September 02, Edesa Biotech, Inc.’s EDSA share price has surged by 5.72%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic, and diagnostic applications in humans and animals; and Yissum Research Development Company for the development of products for therapeutic, prophylactic, and diagnostic uses in topical dermal and anorectal applications, as well as for the use in dermatologic and gastrointestinal conditions. The company was founded in 2015 and is headquartered in Markham, Canada.
Commentary & Analysis
Why Edesa Biotech, Inc.’s (EDSA) Stock Is Up 5.73%
As of Wednesday, August 26, Edesa Biotech, Inc.’s EDSA share price has surged by 5.73%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Edesa Biotech, Inc.’s (EDSA) Stock Is Up 10.56%
As of Wednesday, August 26, Edesa Biotech, Inc.’s EDSA share price has surged by 10.56%, which has investors questioning if this is right time to sell.Tudor Pop
Why Edesa Biotech, Inc.’s (EDSA) Stock Is Up 10.62%
As of Tuesday, August 18, Edesa Biotech, Inc.’s EDSA share price has surged by 10.62%, which has investors questioning if this is right time to sell.Rosalio Madrigal
Why Edesa Biotech, Inc.’s (EDSA) Stock Is Up 10.37%
As of Monday, August 17, Edesa Biotech, Inc.’s EDSA share price has surged by 10.37%, which has investors questioning if this is right time to sell.Michael Rose
Financial Summary
| Share Statistics | EDSA | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $64.6 | $282.5 | 17% |
|
| Shares Out (Mil) | 9.0 | 54.1 | 19% |
|
| Institutional Ownership | 80.7% | 92.9% | 49% |
|
| Float (Mil) | 10.6 | 41.5 | 20% |
|
| Beta | 1.08 | 0.94 | 65% |
|
| Avg Daily Volume (000s) | 138 | 469 | 40% |
|
| Price Change (52-week) |
106.0% | 59.1% | 93% |
|
| Growth | EDSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 14.1% | na |
|
| Net Income (5yr) | (2.4%) | (10.1%) | 37% |
|
| EPS (5yr) | 24.5% | 15.9% | 75 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (0.7%) | (15.6%) | 64% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | na | na | na | |
| Current EPS | na | na | na | |
| Month Ago EPS | na | na | na | |
| # Rev Up | na | na | na | |
| # Rev Down | na | na | na | |
| Three Months Ago EPS | na | na | na | |
| Year/Year Chg | na | na | na | |
| Financials | EDSA | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $37 | na |
|
| Net Income (TTM) (Mil) | ($14) | ($43) | 26% |
|
| EPS (TTM) | ($1.732) | ($1.500) | 16% |
|
| Operating Cash Flow (TTM) (Mil) | ($9) | ($31) | 21% |
|
| Net Cash Flow (TTM) (Mil) | na | $2 | na |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | $44 | $195 | 15% |
|
| Valuation | EDSA | Industry Median |
Percentile (All Stocks) |
|
| P/B | 119.50 | 2.78 | 99% |
|
| P/E | na | 19.4 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | EDSA | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 66.9% | na |
|
| Net Margin | na | (74.2%) | na |
|
| ROA | (102.5%) | (47.6%) | 5% |
|
| ROE | (531.3%) | (55.0%) | 1% |
|
| Liabilities to Assets | 30.7% | 29.6% | 22% |
|
| F-Score | 1 | 3 | 1% |
|
Edesa Biotech, Inc. did not pass any screens on 9/1/2026.
